Metastasis After Radical Prostatectomy or External Beam Radiotherapy for Patients with Clinically Localized Prostate Cancer: a Comparison of Clinical Cohorts Adjusted for Case Mix

Overview

Journal J Clin Oncol

Specialty Oncology

Date 2010 Feb 18

PMID 20159826

Citations 105

Authors

Michael J Zelefsky

James A Eastham

Angel M Cronin

Zvi Fuks

Zhigang Zhang

Yoshiya Yamada

Andrew Vickers

Peter T Scardino

Affiliations

Soon will be listed here.

Abstract

Purpose: We assessed the effect of radical prostatectomy (RP) and external beam radiotherapy (EBRT) on distant metastases (DM) rates in patients with localized prostate cancer treated with RP or EBRT at a single specialized cancer center.

Patients And Methods: Patients with clinical stages T1c-T3b prostate cancer were treated with intensity-modulated EBRT (> or = 81 Gy) or RP. Both cohorts included patients treated with salvage radiotherapy or androgen-deprivation therapy for biochemical failure. Salvage therapy for patients with RP was delivered a median of 13 months after biochemical failure compared with 69 months for EBRT patients. DM was compared controlling for patient age, clinical stage, serum prostate-specific antigen level, biopsy Gleason score, and year of treatment.

Results: The 8-year probability of freedom from metastatic progression was 97% for RP patients and 93% for EBRT patients. After adjustment for case mix, surgery was associated with a reduced risk of metastasis (hazard ratio, 0.35; 95% CI, 0.19 to 0.65; P < .001). Results were similar for prostate cancer-specific mortality (hazard ratio, 0.32; 95% CI, 0.13 to 0.80; P = .015). Rates of metastatic progression were similar for favorable-risk disease (1.9% difference in 8-year metastasis-free survival), somewhat reduced for intermediate-risk disease (3.3%), and more substantially reduced in unfavorable-risk disease (7.8% in 8-year metastatic progression).

Conclusion: Metastatic progression is infrequent in men with low-risk prostate cancer treated with either RP or EBRT. RP patients with higher-risk disease treated had a lower risk of metastatic progression and prostate cancer-specific death than EBRT patients. These results may be confounded by differences in the use and timing of salvage therapy.

Citing Articles

Prognostic Testing for Prostate Cancer-A Cost-Effectiveness Analysis Comparing a Prostatype P-Score Biomarker Approach to Standard Clinical Practice.

Fridhammar A, Frisell O, Wahlberg K, Berglund E, Robeck P, Persson S Pharmacoeconomics. 2025; .

PMID: 39794681 DOI: 10.1007/s40273-024-01466-9.

EXTL3 could serve as a potential biomarker of prognosis and immunotherapy for prostate cancer and its potential mechanisms.

Chang P, Chen S, Chang X, Zhu J, Tang Q, Ma L Eur J Med Res. 2022; 27(1):115.

PMID: 35818069 PMC: 9275153. DOI: 10.1186/s40001-022-00740-w.

The Tobacco β-Cembrenediol: A Prostate Cancer Recurrence Suppressor Lead and Prospective Scaffold via Modulation of Indoleamine 2,3-Dioxygenase and Tryptophan Dioxygenase.

Mudhish E, Siddique A, Ebrahim H, Abdelwahed K, King J, El Sayed K Nutrients. 2022; 14(7).

PMID: 35406118 PMC: 9003379. DOI: 10.3390/nu14071505.

Robot-assisted radical prostatectomy in the treatment of patients with clinically high-risk localized and locally advanced prostate cancer: single surgeons functional and oncologic outcomes.

Shin T, Lee Y BMC Urol. 2022; 22(1):49.

PMID: 35379195 PMC: 8981940. DOI: 10.1186/s12894-022-00998-6.

High-risk Locally Advanced Prostate Cancer: Multimodal Treatment Is the Key.

Terlizzi M, Bossi A Eur Urol Open Sci. 2022; 38:14-16.

PMID: 35199042 PMC: 8844205. DOI: 10.1016/j.euros.2021.07.010.

References

Yamada Y, Bhatia S, Zaider M, Cohen G, Donat M, Eastham J . Favorable clinical outcomes of three-dimensional computer-optimized high-dose-rate prostate brachytherapy in the management of localized prostate cancer. Brachytherapy. 2006; 5(3):157-64. DOI: 10.1016/j.brachy.2006.03.004. View

Pollack A, Zagars G, Starkschall G, Antolak J, Lee J, Huang E . Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002; 53(5):1097-105. DOI: 10.1016/s0360-3016(02)02829-8. View

Eade T, Hanlon A, Horwitz E, Buyyounouski M, Hanks G, Pollack A . What dose of external-beam radiation is high enough for prostate cancer?. Int J Radiat Oncol Biol Phys. 2007; 68(3):682-9. PMC: 2770596. DOI: 10.1016/j.ijrobp.2007.01.008. View

Yossepowitch O, Eggener S, Serio A, Carver B, Bianco Jr F, Scardino P . Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. Eur Urol. 2007; 53(5):950-9. PMC: 2637146. DOI: 10.1016/j.eururo.2007.10.008. View

DAmico A, Manola J, Loffredo M, Renshaw A, DellaCroce A, Kantoff P . 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA. 2004; 292(7):821-7. DOI: 10.1001/jama.292.7.821. View

Pilepich M, Winter K, John M, Mesic J, Sause W, Rubin P . Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys. 2001; 50(5):1243-52. DOI: 10.1016/s0360-3016(01)01579-6. View

van den Ouden D, Hop W, Schroder F . Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy. J Urol. 1998; 160(4):1392-7. DOI: 10.1097/00005392-199810000-00048. View

Zietman A, DeSilvio M, Slater J, Rossi Jr C, Miller D, Adams J . Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005; 294(10):1233-9. DOI: 10.1001/jama.294.10.1233. View

Cahlon O, Zelefsky M, Shippy A, Chan H, Fuks Z, Yamada Y . Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys. 2008; 71(2):330-7. DOI: 10.1016/j.ijrobp.2007.10.004. View

10.

Pilepich M, Winter K, Lawton C, Krisch R, Wolkov H, Movsas B . Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys. 2005; 61(5):1285-90. DOI: 10.1016/j.ijrobp.2004.08.047. View

11.

Kupelian P, Elshaikh M, Reddy C, Zippe C, Klein E . Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy. J Clin Oncol. 2002; 20(16):3376-85. DOI: 10.1200/JCO.2002.01.150. View

12.

Bolla M, Collette L, Blank L, Warde P, Dubois J, Mirimanoff R . Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet. 2002; 360(9327):103-6. DOI: 10.1016/s0140-6736(02)09408-4. View

13.

Fletcher S, Mills S, Smolkin M, Theodorescu D . Case-matched comparison of contemporary radiation therapy to surgery in patients with locally advanced prostate cancer. Int J Radiat Oncol Biol Phys. 2006; 66(4):1092-9. DOI: 10.1016/j.ijrobp.2006.06.019. View

14.

Hanks G, Pajak T, Porter A, Grignon D, Brereton H, Venkatesan V . Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02. J Clin Oncol. 2003; 21(21):3972-8. DOI: 10.1200/JCO.2003.11.023. View

15.

Zelefsky M, Chan H, Hunt M, Yamada Y, Shippy A, Amols H . Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol. 2006; 176(4 Pt 1):1415-9. DOI: 10.1016/j.juro.2006.06.002. View

16.

Freedland S, Partin A, Humphreys E, Mangold L, Walsh P . Radical prostatectomy for clinical stage T3a disease. Cancer. 2007; 109(7):1273-8. DOI: 10.1002/cncr.22544. View

17.

Stephenson A, Scardino P, Eastham J, Bianco Jr F, Dotan Z, Fearn P . Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst. 2006; 98(10):715-7. PMC: 2242430. DOI: 10.1093/jnci/djj190. View

18.

Moul J, Wu H, Sun L, McLeod D, Amling C, Donahue T . Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol. 2004; 171(3):1141-7. DOI: 10.1097/01.ju.0000113794.34810.d0. View

19.

Peeters S, Heemsbergen W, Koper P, van Putten W, Slot A, Dielwart M . Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol. 2006; 24(13):1990-6. DOI: 10.1200/JCO.2005.05.2530. View

20.

Vargas C, Demanes J, Boike T, Barnaba M, Skoolisariyaporn P, Schour L . Matched-pair analysis of prostate cancer patients with a high risk of positive pelvic lymph nodes treated with and without pelvic RT and high-dose radiation using high dose rate brachytherapy. Am J Clin Oncol. 2006; 29(5):451-7. DOI: 10.1097/01.coc.0000221304.74360.8c. View